ClinicalTrials.gg
RecruitingNCT07546760Updated Oct 22, 2026

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

A Phase 1 interventional study of AZD6234 and AZD9550 in Hepatic Impairment, sponsored by AstraZeneca. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 22, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma, Follicular by AstraZeneca — 4 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · AstraZeneca.

Planned enrollment
14th of 16
28 · median 130
Started
2026
the only one that year
Phase 1
7 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Lymphoma, Follicular by AstraZeneca, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 1, and was the 17th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

4 of the 17 studies in Lymphoma, Follicular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Follicular by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Read the detailed description

This Phase I, open-label, parallel group study will investigate the single SC dose PK, safety, tolerability, and immunogenicity of separate administrations of AZD9550 and AZD6234 to male and female participants with severe and moderate hepatic impairment compared to matched controls with normal hepatic function.

To minimize any potential impact from AZD9550 administered in Period 1, AZD6234 will be administered in Period 2 following a washout period. Results from separate injections will ultimately inform the single dose PK, safety, and tolerability of AZD9550 and AZD6234 administered.

Approximately 56 participants will be screened to achieve a total of 16 planned for study intervention (8 per group for CP Class C and CP Class B) with 6 evaluable participants in each of the 2 impairment groups (severe and moderate), and up to 12 participants with normal hepatic function. Initially 8 participants with normal hepatic function will be recruited, matched on a group level regarding sex, age, and BMI to the participants with hepatic impairment. Additional participants with normal hepatic function, up to a total of 12, may be included if needed to meet the matching criteria.

Child-Pugh scoring will be used to determine the level of hepatic impairment. Participants will be enrolled into the following groups based on their CP classification score as determined by a local laboratory at screening:

Group 1: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).

Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).

Group 3: Participants with normal hepatic function matched on a group level regarding sex, age, and BMI to the participants with hepatic impairment

03

Conditions studied

  • Hepatic Impairment

Keywords

  • Moderate
  • Severe
  • Matched Healthy Controls
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-85 years at consent.
  2. Groups:

    • Healthy controls: Medically healthy; no findings in history, exam, labs, vitals, or 12 lead (per investigator).
    • Hepatic impairment: Chronic (≥6 months), stable; documented B (Group 2) or C (Group 1).
  3. Stable concomitant regimen ≥2 weeks before screening (Groups 1-2).
  4. T2DM allowed if \<10% and no severe hypo/hyperglycaemia or hospitalisation within 6 months.
  5. Body weight ≥50 kg; 18-42 kg/m².
  6. Sex assigned at birth (male/female); per local regulations. Females of child bearing potential: negative pregnancy tests and condoms plus one highly effective method through 54 days post last dose. Males: condom use; no sperm donation through 54 days post last dose.
  7. Written ; separate consent for optional genomics.

Exclusion criteria

Exclusion Criteria

Healthy controls only:

  1. Any disease; Diabetes;
  2. lab values i) /AST/ALP >1.5×; ii) WBC/ \<LLN; iii) \<11.0 g/dL (female) or \<12.0 g/dL (male); or PT/INR >1.2×ULN; iv) total >1.5×ULN (or Gilbert's);
  3. abnormal resting vital signs i) SBP >150 or \<90 mmHg, ii) DBP >95 or \<50 mmHg, iii) pulse ≥100 or ≤45 bpm;
  4. >450 ms or clinically significant abnormalities;
  5. severe allergy/;
  6. major surgery within 30 days;
  7. pancreatitis or pancreatic enzymes >2×ULN;
  8. triglycerides >500 mg/dL (5.6 mmol/L);
  9. calcitonin >50 ng/L (50 pg/mL);
  10. severe vitamin D deficiency (\<12 ng/mL, 30 nmol/L);
  11. low corrected or ionised calcium;
  12. positive; surface/core Ab or Ab positive; drug/alcohol abuse within 1 year.

    Hepatically impaired only:

  13. Unstable medical/psychological conditions or uncontrolled systemic disease;
  14. \<50 mL/min/1.73 m² (CKD EPI 2021);
  15. Abnormal resting vital signs i) SBP >160 or \<100 mmHg, ii) DBP >110 or \<65 mmHg, iii) pulse ≥100 or ≤50 bpm;
  16. platelets \<35×10⁹/L; neutrophils \<1.2×10⁹/L; haemoglobin \<85 g/L; ≥10%;
  17. oesophageal banding within 3 months or GI bleeding within 6 months;
  18. ascites requiring paracentesis and albumin ≤4 week intervals; paracentesis within 30 days;
  19. fluctuating/worsening hepatic function during screening; hepatocellular carcinoma;
  20. acute liver disease due to infection/drug; hepatic impairment due to non liver disease;
  21. biliary obstruction or non parenchymal causes; hepatic encephalopathy Grade ≥2;
  22. functioning organ transplant or anticipated within 2 months; prior porto systemic shunt/TIPS;
  23. QTcF >480 ms or clinically significant ECG abnormalities;
  24. pancreatitis or pancreatic enzymes >2×ULN;
  25. triglycerides >500 mg/dL (5.6 mmol/L); calcitonin >50 ng/L (50 pg/mL); severe vitamin D deficiency (\<12 ng/mL, 30 nmol/L); ionised calcium \<LLN;
  26. neoplastic disease within 10 years (except adequately treated BCC/SCC or in situ cervical); MEN2 or medullary thyroid carcinoma (personal or first degree relative); significant gastric emptying abnormality;
  27. HIV positive; HBV surface/core Ab or HCV Ab positive (may be included if HBV DNA or HCV RNA negative on follow up); drug/alcohol abuse within 1 year.
  28. Exposure to a new chemical entity within 30 days or 5 half lives (whichever longer) before intervention; prior exposure to AZD9550 or AZD6234;

    Prior/concomitant therapy:

    Healthy controls:

  29. use of prescription/non prescription/supplements within 7 days (or 14 days for enzyme inducers) or 5 half lives before intervention unless judged non interfering; current oral or oestrogen HRT.

    Hepatically impaired:

  30. prohibited-weight loss medicines (including GLP 1), agents causing significant weight gain (e.g., systemic , antipsychotics), GLP 1 RAs for diabetes, QT prolonging/prokinetic agents, oral contraceptives for contraception; restricted-short systemic glucocorticoids (≤7 days), 5HT 3 antiemetics at lowest effective dose, combined oral contraceptives for non contraceptive indications. If diabetes develops and requires insulin/SU/GLP 1 RA, discontinue from study.

    Other:

  31. prior enrolment in this study (screened without dosing permitted). Positive drugs of abuse and/or alcohol screen (except prescribed meds in hepatic impairment); recent blood products/donation per protocol thresholds; employees or close relatives; vulnerable populations; unlikely to comply (investigator judgement).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants with severe hepatic impairment (CP Class C, score of 10 to 15).

    Drug: AZD6234 · Drug: AZD9550

  • Experimental
    Group 2

    Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).

    Drug: AZD6234 · Drug: AZD9550

  • Experimental
    Group 3

    Participants with normal hepatic function matched on a group level regarding sex, age, and BMI to the participants with hepatic impairment.

    Drug: AZD6234 · Drug: AZD9550

Interventions

  • Single subcutaneous dose of AZD6234 in participants from all groups

  • Single subcutaneous dose of AZD9550 in participants from all groups

06

What researchers measure

Primary outcomes

  1. PK parameters AUCinf

    To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

  2. PK parameters AUClast

    To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

  3. PK parameters Cmax

    To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

Secondary outcomes

  1. PK parameters tmax

    To evaluate the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment and matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

  2. Prevalence and incidence of ADAs to AZD9550 and AZD6234

    To evaluate the immunogenicity of AZD9550 and AZD6234 following separate single SC doses of AZD9550 and AZD6234

    Time frame: Day 0 through Day 56

  3. PK parameters t1/2λz

    To evaluate the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment and matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

  4. PK parameters CL/F

    To evaluate the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment and matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

  5. PK parameters Vz/F

    To evaluate the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment and matched controls with normal hepatic function

    Time frame: Day 0 through Day 56

Other outcomes

  1. Incidence of AEs, SAEs

    To assess the safety and tolerability of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment and matched controls with normal hepatic function

    Time frame: Screening through Day 56

07

Study locations

3 of 4 sites recruiting
  • Research Site
    Chandler, Arizona 85225, United States
    Recruiting
  • Research Site
    Rialto, California 92377, United States
    Terminated

    Not enrolling at this site.

  • Research Site
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's planned 10 months is below that.

Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Apr 23, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Feb 4, 2027
CompletionEst.
Feb 4, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Terminated
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Research Site is now Terminated
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546760
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Mar 20, 2026
Primary completion
Feb 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD6234 · AZD9550

Start the discussion